TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02981290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Renodapt
Description: Renodapt will be administered as 500 milligrams (mg) tablet orally on Day 1 in any treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Renodapt
Description: Renodapt will be administered as 500 milligrams (mg) tablet orally on Day 1 in any treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Renodapt
Description: Renodapt will be administered as 500 milligrams (mg) tablet orally on Day 1 in any treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Renodapt
Description: Renodapt will be administered as 500 milligrams (mg) tablet orally on Day 1 in any treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycept
Description: Mycept will be administered as 500 mg tablet orally on Day 1 in any treatment periods.
Study: NCT03126149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06667272
Description: Single ascending dose of PF-06667272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06667272
Description: Single ascending dose of PF-06667272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06667272
Description: Single ascending dose of PF-06667272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06667272
Description: Single ascending dose of PF-06667272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06667272
Description: Single ascending dose of PF-06667272

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of placebo
Study: NCT02967029

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esmolol Hydrochloride
Description: the influence of brevibloc as a hypotensive agent on rSO2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil Hydrochloride
Description: the influence of remifentanyl as a hypotensive agent on rSO2
Study: NCT00564408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbachol
Description: 3 microgram per kg bodyweight infused intravenously
Study: NCT02803450

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epidural needle
Description: Medication administration via epidural needle.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheter Administration
Description: Medication administration via epidural catheter.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Epidural Administration
Description: Medication administered at higher concentration, lower volume via epidural catheter.
Study: NCT01316055

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dalfampridine-ER
Description: 2 days of single dose 7.5 mg, 4 days of bid dosing, and a 3 day follow-up

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dalfampridine-ER
Description: 2 days of single dose 7.5 mg, 4 days of bid dosing, and a 3 day follow-up

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dalfampridine-ER
Description: 2 days of single dose 7.5 mg, 4 days of bid dosing, and a 3 day follow-up
Study: NCT00131391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: taranabant
Description: taranabant 2 mg capsule, 4 mg capsule, 6 mg capsule. 52 week treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: taranabant
Description: taranabant 2 mg capsule, 4 mg capsule, 6 mg capsule. 52 week treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: taranabant
Description: taranabant 2 mg capsule, 4 mg capsule, 6 mg capsule. 52 week treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: taranabant
Description: taranabant 2 mg capsule, 4 mg capsule, 6 mg capsule. 52 week treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: taranabant
Description: taranabant 2 mg capsule, 4 mg capsule, 6 mg capsule. 52 week treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: placebo
Description: Placebo capsule once daily . 52 week treatment period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo
Description: Placebo capsule once daily . 52 week treatment period.
Study: NCT01450592

Intervention type: OTHER
Intervention: No drug
Description: Diabetic Population
Study: NCT00690898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide autogel 120 mg
Description: 12 months
Study: NCT01360476

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol (Vitamin D)
Description: 50,000 UI, chewable wafer every 2 weeks for 52 weeks (27 total doses)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: chewable wafer every 2 weeks for 52 weeks (27 total doses)
Study: NCT01450592

Intervention type: OTHER
Intervention: No drug
Description: Non-Diabetic Population
Study: NCT01178931

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral dydrogesterone
Description: oral-2x10mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crinone 8% gel
Description: vaginal-1x90mg
Study: NCT04270773

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Human Papillomavirus 9-valent Vaccine, Recombinant
Description: Vaccine administrated
Study: NCT02355834

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IBD nurse intervention
Description: Two IBD nurse specialists at each centre (8 in total) will deliver the IBD nurse intervention
Study: NCT06552026

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repeated transcranial magnetic stimulation
Description: repetitive transcranial magnetic stimulation by use of high-frequency (10 Hz) left-side DLPFC stimulation is currently widely used in the treatment of depression17.Intermittent theta burst stimulation (iTBS) is a newer form of rTMS that can be delivered with shorter duration of stimulation sessions and apparent efficacy at lower stimulation intensities18. Both 10 Hz and intermittent theta burst stimulation pulses have an excitatory effect on cortical excitability

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repeated transcranial magnetic stimulation
Description: repetitive transcranial magnetic stimulation by use of high-frequency (10 Hz) left-side DLPFC stimulation is currently widely used in the treatment of depression17.Intermittent theta burst stimulation (iTBS) is a newer form of rTMS that can be delivered with shorter duration of stimulation sessions and apparent efficacy at lower stimulation intensities18. Both 10 Hz and intermittent theta burst stimulation pulses have an excitatory effect on cortical excitability
Study: NCT02295449

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: biopsy sample performed after the SonoVue® injection
Study: NCT00639379

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A toric
Description: silicone hydrogel toric lens, 2 wk replacement, daily wear

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: alphafilcon A toric
Description: hydrogel toric lens, 2 wk replacement, daily wear
Study: NCT03105947

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Coconut oil
Description: 50g extravirgin coconut oil daily for four weeks
Study: NCT01567085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Study: NCT01452087

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: Subjects will exercise on a treadmill for 1 hour at moderate intensity (i.e., 90% of the exercise intensity found to elicit their ventilatory threshold during the preliminary testing, which is equivalent to approximately 60% of their maximal predicted heart rate).
Study: NCT00115531

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine
Description: Standard Dose Influenza Vaccine Fluzone® (15 µg HA / viral strain; 45 µg/0.5 mL dose) will be administered to Arm 1: 200 subjects intramuscularly on day 0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine
Description: High Dose Influenza Fluzone® Vaccine (60 µg HA / viral strain; 180 µg/0.5 mL dose) will be administered to Arm 2: 200 subjects intramuscularly on Day 0.
Study: NCT01996995

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser pulse therapy

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: Sham procedure
Study: NCT03076242

Intervention type: OTHER
Intervention: GEM Registry
Description: Men with a personal history of PCA; Unaffected males who are at higher risk for prostate cancer
Study: NCT02545192

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Field Magnetic Stimulation
Description: The LFMS Device is an electromagnetic coil situated on a cylinder with an inside diameter of 13.2 inches. It produces weak electromagnetic fields at a frequency of about 1000Hz; the magnetic fields are less than 30 Gauss and the electric fields are up to 1.43 V/m. A fully detailed description of the electromagnetic field distribution and waveform has been presented in the IDE submission to the FDA (and determined to be a non-significant risk device).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Low Field Magnetic Stimulation
Description: The LFMS Device is an electromagnetic coil situated on a cylinder with an inside diameter of 13.2 inches. It produces weak electromagnetic fields at a frequency of about 1000Hz; the magnetic fields are less than 30 Gauss and the electric fields are up to 1.43 V/m. A fully detailed description of the electromagnetic field distribution and waveform has been presented in the IDE submission to the FDA (and determined to be a non-significant risk device).
Study: NCT03426150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPP-ACP
Description: The surfaces of specimens were pretreated with CPP-ACP for 3 min

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: The surfaces of specimens were pretreated with deionized water for 3 min
Study: NCT03530228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegoprazan (C1)
Description: Tegoprazan QD, oral administration. Treatment A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegoprazan (C1)
Description: Tegoprazan QD, oral administration. Treatment B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C: Tegoprazan (C1)
Description: Tegoprazan BID, oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegoprazan (C2)
Description: Tegoprazan QD, oral administration, for 7 days. Group 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegoprazan (C2)
Description: Tegoprazan QD, oral administration, for 7 days. Group 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole (C2)
Description: Esomeprazole QD, oral administration, for 7 days. Group 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegoprazan (C3)
Description: Tegoprazan QD, oral administration
Study: NCT03105947

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Butter
Description: 50g butter daily for four weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Olive oil
Description: 50g extra virgin olive oil daily for four weeks
Study: NCT03480074

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Staple Ligation
Description: Using a stapler that staples the DVC and then cuts it.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Selective Suture Ligation
Description: Suture the DVC, suspend it to the pubic bone, and then cut.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single Suture Ligation
Description: Cut the DVC, then pinpoint a specific blood vessel needed to sew/suture.
Study: NCT02451878

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-Couch
Description: e-couch is an online CBT based intervention
Study: NCT00296595

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Nutrition
Study: NCT03049566

Intervention type: OTHER
Intervention: preoperative questionnaires
Description: no intervention, cross-sectional survey in a single group
Study: NCT02513199

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Radiation is to be delivered to 30-45 Gy in 5 fractions. 40 Gy in 5 fractions will be utilized, unless dose constraints preclude it. Treatment will optimally be delivered every other day with no more than 3 fractions per week. The ideal treatment team will be less than 15 total days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TACE
Description: two sessions of standard TACE with ethiodol separated by a 4-week interval.
Study: NCT00766220

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SIR-spheres Agent Administration
Description: SIR-Spheres, resin microspheres containing pure Beta emitter Yttrium-90, given through femoral catheter over 10 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: 400 mg/m2 by vein over 2 hours once a week.~Cetuximab infusions will be continued weekly at a dose of 250 mg/m2 unless toxicity necessitates interruptions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: 400 mg/m2 by vein over 2 hours once a week.~Cetuximab infusions will be continued weekly at a dose of 250 mg/m2 unless toxicity necessitates interruptions.
Study: NCT00883233

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adapalene BPO Gel standard daily overnight application
Description: Adapalene 0.1% /Benzoyl Peroxide 2.5% Gel standard daily overnight application for 12 week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene-BPO 3-hour daily application before bedtime
Description: Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel 3-hour daily application before bedtime for first 4 weeks and then standard overnight daily application for the following 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene-BPO Gel every other day application
Description: Adapalene 0.1% /Benzoyl Peroxide 2.5% Gel every other day application for the first 4 weeks and then standard overnight daily application for the following 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene-BPO Gel standard+Cetaphil® Moisturizing Lotion
Description: Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel standard daily overnight application with Cetaphil® Moisturizing Lotion application at wake-up time for the first 4 weeks and then standard daily overnight application for the following 8 weeks
Study: NCT04583657

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Eggs
Description: Consumption of two eggs (control or test) per day during three months
Study: NCT00766220

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: 350 mg/m2 (or 300 mg/m2 in patients who are greater or equal to 70 years of age, or have an ECOG PS of 2 or have had prior pelvic and/or abdominal irradiation), by vein over 90 minutes, every three weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: 350 mg/m2 (or 300 mg/m2 in patients who are greater or equal to 70 years of age, or have an ECOG PS of 2 or have had prior pelvic and/or abdominal irradiation), by vein over 90 minutes, every three weeks.
Study: NCT02981290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycept
Description: Mycept will be administered as 500 mg tablet orally on Day 1 in any treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycept
Description: Mycept will be administered as 500 mg tablet orally on Day 1 in any treatment periods.
Study: NCT02855554

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac Magnetic Resonance (CMR) imaging techniques
Description: Evaluation of clinical potential of fast quantitative myocardial tissue characterization using recently emerged CMRI techniques to aid the diagnosis, treatment, and follow up of patients with myocardial diseases.
Study: NCT02981290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycept
Description: Mycept will be administered as 500 mg tablet orally on Day 1 in any treatment periods.
Study: NCT04583657

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eggs
Description: Consumption of two eggs (control or test) per day during three months
Study: NCT03408665

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: 3 sessions at least, up to 6. Neither specifc device is imposed.
Study: NCT00833937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg tablets
Description: 1 x 10 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMBIEN® 10 mg tablets
Description: 1 x 10 mg
Study: NCT01944072

Intervention type: OTHER
Group type: OTHER
Intervention: Aerobic exercise training intensity

Intervention type: OTHER
Group type: OTHER
Intervention: Aerobic exercise training intensity
Study: NCT05367986

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electro-acupuncture
Description: Electro-acupuncture was given at the Zusanli (ST36), Guanyuan (CV4), and Qihai (CV6) acupoints, twice a day for 30 minutes, and for 5 days in total.~1. Acupoints were selected as follows. (1) Zusanli (ST36) belongs to zuyangming stomach meridian. It is located on the anterolateral part of the lower leg 3 inches (4 horizontal fingers) below the eye of the external knee between the fibula and the tibia, and a horizontal finger (middle finger) width from the front edge of the tibia. (2) Guan yuan (CV4) is located 3 inches below the umbilicus, on the midline of the abdomen. (3) Qihai (CV6) is located 1.5 inches below the umbilicus on the midline.~2. Acupuncture and electro-acupuncture methods were performed as follows. Participants were in the supine position, and needles was inserted in the skin . After the participant has acid, numbness, swelling, pain or other feelings, the electro-acupuncture device was connect to the acupuncture needle, the frequency was set to continuous wave.
Study: NCT00614393

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dalotuzumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dalotuzumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dalotuzumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dalotuzumab
Description: IV infusion
Study: NCT02981290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cellmune
Description: Cellmune will be administered as 500 mg tablet orally on Day 1 in any treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cellmune
Description: Cellmune will be administered as 500 mg tablet orally on Day 1 in any treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cellmune
Description: Cellmune will be administered as 500 mg tablet orally on Day 1 in any treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cellmune
Description: Cellmune will be administered as 500 mg tablet orally on Day 1 in any treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CellCept
Description: CellCept will be administered as 500 mg tablet orally on Day 1 in any treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CellCept
Description: CellCept will be administered as 500 mg tablet orally on Day 1 in any treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CellCept
Description: CellCept will be administered as 500 mg tablet orally on Day 1 in any treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CellCept
Description: CellCept will be administered as 500 mg tablet orally on Day 1 in any treatment periods.
Study: NCT02053805

Intervention type: OTHER
Group type: OTHER
Intervention: PSA
Description: PSA. Serum \& plasma will be stored for future investigations

Intervention type: OTHER
Group type: OTHER
Intervention: IPSS questionnaire
Description: the validated International Prostate Symptom Score

Intervention type: OTHER
Group type: OTHER
Intervention: DRE (Digital Rectal Examination )
Description: physical examination for the prostate gland
Study: NCT01649011

Intervention type: BEHAVIORAL
Intervention: Application of the initial evaluation
Description: Initial evaluation involves the application of the previously spanish validated Rolland Morris Questionnaire and the new spanish Oswestry Disability Index

Intervention type: BEHAVIORAL
Intervention: Final application of scales
Description: Application of the previously spanish validated version of the RMQ and the new spanish translation of the ODI 2 weeks after initial evaluation
Study: NCT00614393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: IV infusion
Study: NCT00556322

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alimta or Taxotere
Description: 500mg/m2 / 3 weeks (Alimta) or 75mg/m2 / 3 weeks (Taxotere)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib [Tarceva]
Description: 150mg po daily
Study: NCT01915186

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dihydroepiandrosterone (DHEA)
Description: DHEA capsules are given at 25mg 3 times a day for 12 weeks
Study: NCT01383694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperine
Study: NCT03700723

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Resusix
Description: spray-dried solvent/detergent treated plasma (blood product)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FP24 (Frozen Plasma)
Description: plasma frozen within 24 hours of phlebotomy